[HTML][HTML] ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
Heterogeneity of triple negative breast cancer: Current advances in subty** and treatment implications
As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS …
HS Rugo, A Bardia, F Marmé, J Cortés, P Schmid… - The Lancet, 2023 - thelancet.com
Background Sacituzumab govitecan demonstrated significant progression-free survival
benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated …
benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated …
Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database
Importance Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine
kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally …
kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally …
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA …
Background HER2-low breast cancer (BC) is currently an area of active interest. This study
evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative …
evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative …
[HTML][HTML] 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
This manuscript describes the Advanced Breast Cancer (ABC) international consensus
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly
defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast …
defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast …
Current biological, pathological and clinical landscape of HER2-low breast cancer
H Zhang, Y Peng - Cancers, 2022 - mdpi.com
Simple Summary The breakthrough in develo** novel HER2-targeting antibody drug
conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically …
conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically …
[HTML][HTML] Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant …
Background The interest in HER2-low breast cancer (BC) has increased in recent years with
the development of novel anti-HER2 antibody–drug conjugates. Here, we investigated the …
the development of novel anti-HER2 antibody–drug conjugates. Here, we investigated the …
Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experience
H Xu, Y Han, Y Wu, Y Wang, Q Li, P Zhang… - Frontiers in …, 2022 - frontiersin.org
Background Human epidermal growth factor 2 (HER2)-low breast cancer, which is defined
as HER2 1+ or 2+ in immunohistochemistry without gene amplification, accounts for a …
as HER2 1+ or 2+ in immunohistochemistry without gene amplification, accounts for a …